Legend Biotech Corporation (LEGN) is emerging as a significant entity in the biotechnology sector, particularly recognized for its innovative advancements in oncology. The company's flagship product, CARVYKTI, a pioneering multiple myeloma therapy, has been a central driver of its recent financial successes. In 2025, CARVYKTI recorded impressive net trade sales of approximately $555 million in the fourth quarter, contributing to an annual total of $1.9 billion. This strong performance has led the CARVYKTI franchise to achieve full-year profitability, reflecting the therapy's profound impact and market acceptance. This financial triumph is further bolstered by a substantial increase in collaboration revenue, which reached $277.6 million in the last quarter of 2025.

The company's commitment to patient care and operational expansion is evident in its strategic initiatives. By 2025, Legend Biotech had successfully treated over 10,000 patients with CARVYKTI across various clinical and commercial settings, marking a crucial clinical milestone. To cater to the escalating demand for its therapy, Legend Biotech undertook a significant expansion of its Raritan manufacturing facility. This expansion has transformed it into the largest cell therapy production site in the United States, now equipped with the capacity to treat 10,000 patients annually. Furthermore, the global footprint of CARVYKTI has broadened to encompass 294 sites across 14 markets, with a deliberate emphasis on enhancing its accessibility within US community and outpatient environments. Continuous presentation of new data at key medical conferences consistently underscores the lasting efficacy of CARVYKTI when utilized in earlier stages of treatment. Beyond its primary offering, Legend Biotech is actively nurturing its early-stage pipeline and research capabilities, highlighted by the inauguration of a new 31,000-square-foot R&D facility in Philadelphia and the commencement of first-patient dosing for its in vivo pipeline candidates.

Legend Biotech Corporation, a clinical-stage biotechnology firm, specializes in the discovery, development, manufacturing, and commercialization of groundbreaking therapies for cancer and other medical conditions. The company is at the forefront of developing advanced cell therapies, leveraging a diverse array of technology platforms to innovate and bring new treatments to patients. While Legend Biotech presents a compelling investment opportunity due to its strong performance and pipeline, investors are encouraged to explore a broader range of growth stocks and emerging sectors, such as AI, for diversified potential returns.